To reverse or not to reverse: An evaluation of reversal of mivacurium chloride in women undergoing outpatient gynecological procedures

Jonathan S. Jahr, Todd Keller, Matthew D. Williams, John R. Liukkonen, Muhammad Anwar, Carlos G. Paxtor, Monica Greene, Melvin C. Gitlin

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Background: A double-blind, randomized study compared differences between patients administered edrophonium and those administered placebo after mivacurium infusion. Neuromuscular blockade was quantified using the ParaGraph 1800 nerve stimulator-monitor (Vital Signs, Totowa, NJ), which can deliver a train-of-four stimulus to the ulnar nerve and quantify the ratio of the fourth twitch to the first twitch. Methods: With Investigational Review Board approval and informed consent, 30 healthy outpatient gynecological surgery patients ASA I or II, aged 21 to 37 years, were randomly assigned to treatment or placebo. In a double-blind manner, one group received edrophonium (1 mg/kg) and atropine (0.01 mg/kg) reversal (E/A) and the other group received placebo (P) to recover spontaneously from a mivacurium infusion. Anesthesia was induced and a rapid infusion of mivacurium chloride (0.2 mg/kg) was administered. An infusion of mivacurium chloride was then initiated at a rate of 6-7 μg/kg/min to maintain neuromuscular blockade. Group differences in recovery time (time between administration of the edrophonium or placebo and a 5-second head lift followed by tracheal extubation) were compared, as was time from tracheal extubation to discharge from the postanesthesia care unit (PACU). Nausea and vomiting were documented until the patient was discharged from the hospital; a 24-hour follow-up evaluation was completed by telephone. Results: Each group contained 15 patients, and their demographics were similar. The mean recovery time for E/A was statistically shorter than for P (P, 9.7 ± 4.8 minutes; E/A, 6.1 ± 3.9 minutes; p = 0.017). There were no statistically significant differences found in the incidence of nausea and vomiting (P, 4; E/A, 6) or in time to discharge from the PACU. Conclusion: Recovery from a mivacurium chloride infusion is shorter by 3.6 minutes (margin of error ± 3.3 minutes) when reversal with edrophonium/atropine is used. There is no difference in time to discharge from PACU and no evidence of differences in nausea and vomiting.

Original languageEnglish (US)
Pages (from-to)315-322
Number of pages8
JournalAmerican journal of therapeutics
Volume4
Issue number9-10
DOIs
StatePublished - Jan 1 1997

Keywords

  • Anesthesia
  • Edrophonium
  • Laparoscopy
  • Mivacurium
  • Outpatient
  • ParaGraph nerve monitor-stimulator
  • Tubal ligation

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'To reverse or not to reverse: An evaluation of reversal of mivacurium chloride in women undergoing outpatient gynecological procedures'. Together they form a unique fingerprint.

  • Cite this

    Jahr, J. S., Keller, T., Williams, M. D., Liukkonen, J. R., Anwar, M., Paxtor, C. G., Greene, M., & Gitlin, M. C. (1997). To reverse or not to reverse: An evaluation of reversal of mivacurium chloride in women undergoing outpatient gynecological procedures. American journal of therapeutics, 4(9-10), 315-322. https://doi.org/10.1097/00045391-199709000-00006